Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the efficacy and safety of intra-articular etanercept in patients with refractory knee joint synovitis: a placebo controlled, single-blind, crossover-trial, with randomisation of treatment sequence

Next Previous
Search
Trial Profile

Evaluation of the efficacy and safety of intra-articular etanercept in patients with refractory knee joint synovitis: a placebo controlled, single-blind, crossover-trial, with randomisation of treatment sequence

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary)
  • Indications Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Synovitis
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Jun 2009 Results were reported at the 10th Annual Congress of the European League Against Rheumatism.
    • 06 Jun 2008 New trial record.
    • 11 Nov 2007 Interim results in 25 patients presented at ACR 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top